Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Hengrui Medicine: SHR-2524 Injection Clinical Trial Approved
People’s Financial News, March 11 — Hengrui Medicine (600276) announced on March 11 that recently, its subsidiary Suzhou Shengdia Biopharmaceutical Co., Ltd. received the approval notice from the National Medical Products Administration for the clinical trial of SHR-2524 injection. The clinical trial will commence soon. This drug is a self-developed biological product classified as Category 2.1 and 2.3 for therapeutic use, intended for the treatment of hepatocellular carcinoma.